Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.
The Editors welcome:
Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology
Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug
The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.
《Expert Opinion On Drug Discovery》是一本由TAYLOR & FRANCIS LTD出版商出版的專業醫學期刊,該刊創刊于2006年,刊期Bimonthly,該刊已被國際權威數據庫SCIE收錄。在中科院最新升級版分區表中,該刊分區信息為大類學科:醫學 2區,小類學科:藥學 2區;在JCR(Journal Citation Reports)分區等級為Q1。該刊發文范圍涵蓋藥學等領域,旨在及時、準確、全面地報道國內外藥學工作者在該領域取得的最新研究成果、工作進展及學術動態、技術革新等,促進學術交流,鼓勵學術創新。2021年影響因子為7.05,平均審稿速度較慢,6-12周。
大類學科 | 分區 | 小類學科 | 分區 | Top期刊 | 綜述期刊 |
醫學 | 3區 | PHARMACOLOGY & PHARMACY 藥學 | 3區 | 否 | 是 |
JCR分區等級 | JCR所屬學科 | 分區 | 影響因子 |
Q1 | PHARMACOLOGY & PHARMACY | Q1 | 7.05 |
影響因子 | h-index | Gold OA文章占比 | 研究類文章占比 | OA開放訪問 | 平均審稿速度 |
7.05 | 50 | 10.24% | 0.00% | 未開放 | 較慢,6-12周 |